Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases

Journal of Medicinal Chemistry

Volumn 58, Issue 2, 2015, Pages 897-911

  Lemurell, Malin ^a   Ulander, Johan ^a   Winiwarter, Susanne ^a   Dahlén, Anders ^a   Davidsson, Öjvind ^a   Emtenäs, Hans ^a   Broddefalk, Johan ^a   Swanson, Marianne ^a   Hovdal, Daniel ^a   Plowright, Alleyn T ^a   Pettersen, Anna ^a   Rydén Landergren, Marie ^a   Barlind, Jonas ^a   Llinas, Antonio ^a   Herslöf, Margareta ^a   Drmota, Tomas ^a   Sigfridsson, Kalle ^a   Moses, Sara ^a   Whatling, Carl ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 [2 [4 (5 AMINOPYRAZIN 2 YL)PHENYL]TETRAHYDROFURAN 2 YL]N(2 HYDROXY 2 METHYLPROPYL)PYRIDINE 2 CARBOXAMIDE; 5 [2 [4 (BENZYLOXY)PHENYL]TETRAHYDROFURAN 2 YL] 2 BROMOPYRIDINE; ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; CARBON; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; LEUKOTRIENE B4; METHYL 5 [2 [4 (BENZYLOXY)PHENYL]TETRAHYDROFURAN 2 YL]PYRIDINE 2 CARBOXYLATE; N(2 HYDROXY 2 METHYLPROPYL) 5 [2 (4 HYDROXYPHENYL)TETRAHYDROFURAN 2 YL]PYRIDINE 2 CARBOXAMIDE; TETRAHYDROFURAN; UNCLASSIFIED DRUG; [4 (BENZYLOXY)PHENYL](6 BROMOPYRIDIN 3 YL)METHANONE; 5-(2-(4-(5-AMINOPYRAZIN-2-YL)PHENYL)TETRAHYDROFURAN-2-YL)-N-(2-HYDROXY-2-METHYLPROPYL)PYRIDINE-2-CARBOXAMIDE; PICOLINIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; ATOM; CHIRAL CHROMATOGRAPHY; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; EX VIVO STUDY; EXPERIMENTAL DOG; HUMAN; HUMAN CELL; HYDROPHILICITY; IC50; INTRINSIC CLEARANCE; LIPOPHILICITY; METABOLITE; NONHUMAN; PHYSICAL CHEMISTRY; RAT; REDUCTION; RING CLOSING METATHESIS; STRUCTURE ACTIVITY RELATION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; DOG; DRUG DEVELOPMENT; SOLUBILITY; STEREOISOMERISM; SYNTHESIS; X RAY DIFFRACTION;

5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; DOGS; DRUG DISCOVERY; HUMANS; PICOLINIC ACIDS; PYRAZINES; RATS; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; X-RAY DIFFRACTION;

EID: 84921490348     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501531v     Document Type: Article

References (34)

1. Peters-Golden, M. Cell biology of the 5-lipoxygenase pathway. Am. J. Respir. Crit. Care Med. 1998, 157, 227-232, 247-248.
2. Sala, A.; Folco, G.; Murphy, R. C. Transcellular biosynthesis of eicosanoids Pharmacol. Rep. 2010, 62, 503-510
3. Folco, G.; Murphy, R. C. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses Pharmacol. Rev. 2006, 58, 375-388
4. Matsuse, H.; Kohno, S. Leukotriene receptor antagonists pranlukast and montelukast for treating asthma Expert Opin. Pharmacother. 2014, 15, 353-363
5. Whatling, C.; McPheat, W.; Hersloef, M. The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field Expert Opin. Invest. Drugs 2007, 16, 1879-1893
6. Hakonarson, H.; Thorvaldsson, S.; Helgadottir, A.; Gudbjartsson, D.; Zink, F.; Andresdottir, M.; Manolescu, A.; Arnar, D. O.; Andersen, K.; Sigurdsson, A.; Thorgeirsson, G.; Jonsson, A.; Agnarsson, U.; Bjornsdottir, H.; Gottskalksson, G.; Einarsson, A.; Gudmundsdottir, H.; Adalsteinsdottir, A. E.; Gudmundsson, K.; Kristjansson, K.; Hardarson, T.; Kristinsson, A.; Topol, E. J.; Glucher, J.; Kong, A.; Gurney, M.; Thorgeirsson, G.; Stefansson, K. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction. A randomized trial JAMA, J. Am. Med. Assoc. 2005, 293, 2245-2256
7. Tardif, J.; L'allier, P. L.; Ibrahim, R.; Gregoire, J. C.; Nozza, A.; Cossette, M.; Kouz, S.; Lavoie, M.; Paquin, J.; Brotz, T. M.; Taub, R.; Pressacco, J. Treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) in patients with recent acute coronary syndrome Circ. Cardiovasc. Imaging 2010, 3, 298-307
8. Lorrain, D. S.; Bain, G.; Correa, L. D.; Chapman, C.; Broadhead, A. R.; Santini, A. M.; Prodanovich, P. P.; Darlington, J. V.; Stock, N. S.; Zunic, J.; King, C. D.; Lee, C.; Baccei, C. S.; Stearns, B.; Roppe, J.; Hutchinson, J. H.; Prasit, P.; Evans, J. F. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation Eur. J. Pharmacol. 2010, 640, 211-218
9. Ogawa, A.; Ujjainwalla, F.; Vande Bunte, E. K.; Chu, L.; Ondeyka, D.; Kopka, I.; Li, B.; Ok, H.; Patel, M. J.; Xu, J.; Sisco, R. WO2008030369 A1, 2008.
10. Ogawa, A.; Ujjainwalla, F.; Vande Bunte, E. K.; Chu, L.; Ondeyka, D.; Kopka, I. E.; Li, B.; Ok, H. O.; Patel, M.; Sisco, R. WO2008156721 A1, 2008.
11. Ogawa, A.; Ujjainwalla, F.; Li, B.; Chu, L.; Patel, M.; Armstrong, H.; Ok, H. O.; Sisco, R.; MacDonald, D.; Hutchinson, J.; Perrier, H. WO2009048547 A1, 2009.
12. Evans, J. F.; Ferguson, A. D.; Mosley, R. T.; Hutchinson, J. H. What's all the FLAP about?: 5-Lipoxygenase-activating protein inhibitors for inflammatory diseases Trends Pharmacol. Sci. 2008, 29, 72-78
13. Ferguson, A. D.; McKeever, B. M.; Xu, S.; Wisniewski, D.; Miller, D. K.; Yamin, T.; Spencer, R. H.; Chu, L.; Ujjainwalla, F.; Cunningham, B. R.; Evans, J. F.; Becker, J. W. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein Science 2007, 317, 510-512
14. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
15. Gleeson, M. P.; Hersey, A.; Montanari, D.; Overington, J. Probing the links between in vitro potency, ADMET and physicochemical parameters Nat. Rev. Drug Discovery 2011, 10, 197-208
16. Peters, J.; Schnider, P.; Mattei, P.; Kansy, M. Pharmacological promiscuity: dependence on compound properties and target specifity in a set of recent Roche Ccompounds ChemMedChem 2009, 4, 680-686
17. Chambers, R. J.; Marfat, A. Regiospecific carboalkoxylation of 2,5-dibromopyridine Synth. Commun. 1997, 27, 515-520
18. Marxer, A. Ringslutning mha NaH/butylbromide Helv. Chim. Acta 1969, 52, 262-270
19. Gierczyk, B.; Nowak-Wydra, B.; Schroeder, G. Oxadiazole synthesis Magn. Reson. Chem. 2003, 41, 689-692
20. El-Azzounyl, A. A.; Maklad, Y. A.; Bartsch, H.; Zaghary, W. A.; Ibrahim, W. M.; Mohamed, M. S. Hydroxyoxadiazoles Sci. Pharm. 2003, 71, 331-356
21. Ogawa, A.; Ujjainwalla, F.; Vande Bunte, E. K.; Chu, L.; Ondeyka, D.; Kopka, I. E.; Li, B.; Ok, H. O.; Patel, M.; Sisco, R. Diphenyl Substituted Alkanes. WO2008/156721 A1, 2008; Merck and Co.
22. Vozza, J. F. ringslutningar under sura betingelser av difenyl-butandioler till difenyl-THF J. Org. Chem. 1959, 24, 720-722
23. Gabrielsson, J.; Dolgos, H.; Gillberg, P.; Bredberg, U.; Benthem, B.; Duker, G. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations Drug Discovery Today 2008, 14, 358-372
24. Green, A. R.; Gabrielsson, J.; Marsden, C. A.; Fone, K. C. F. MDMA: on the translation from rodent to human dosing Psychopharmacology (Berlin, Ger.) 2009, 204, 375-378
25. Yang, C.; Hasselgren, C. H.; Boyer, S.; Arvidson, K.; Aveston, S.; Dierkes, P.; Benigni, R.; Benz, R. D.; Contrera, J.; Kruhlak, N. L.; Matthews, E. J.; Han, X.; Jaworska, J.; Kemper, R. A.; Rathman, J. F.; Richard, A. M. Understanding genetic toxicity through data mining: the process of building knowledge by integrating multiple genetic toxicity databases Toxicology Mech. Methods 2008, 18, 277-295
26. Kazius, J.; McGuire, R.; Bursi, R. Derivation and validation of toxicophores for mutagenicity prediction J. Med. Chem. 2005, 48, 312-320
27. Maron, D. M.; Ames, B. N. Revised methods for the Salmonella mutagenicity test Mutat. Res., Environ. Mutagen. Relat. Subj. 1983, 113, 173-215
28. Zhang, L.; Zhang, Y. D.; Zhao, P.; Huang, S. M. Predicting drug-drug interactions: an FDA perspective AAPS J. 2009, 11, 300-306
29. Baillie, T. A. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism Chem. Res. Toxicol. 2008, 21, 129-137
30. Baillie, T. A. The use of stable isotopes in pharmacological research Pharmacol. Rev. 1981, 33, 81-132
31. McGinnity, D. F.; Collington, J.; Austin, R. P.; Riley, R. J. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs Curr. Drug Metab. 2007, 8, 463-479
32. Uematsu, T.; Kanamaru, M.; Kosuge, K.; Hara, K.; Uchiyama, N.; Takenaga, N.; Tanaka, W.; Friedman, B. S.; Nakashima, M. Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers Br. J. Clin. Pharmacol. 1995, 40, 59-66
33. Bain, G.; King, C. D.; Schaab, K.; Rewolinski, M.; Norris, V.; Ambery, C.; Bentley, J.; Yamada, M.; Santini, A. M.; van de Wetering de Rooij, J.; Stock, N.; Zunic, J.; Hutchinson, J. H.; Evans, J. F. Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor Br. J. Clin. Pharmacol. 2013, 75, 779-790
34. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; Macintyre, F.; Rance, D. J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data J. Pharmacol. Exp. Ther. 1997, 283, 46-58